{"id":"nicord-omidubicel","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft-versus-host disease (GVHD)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Delayed engraftment"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL4298190","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NiCord® consists of CD34+ cells from umbilical cord blood that have been expanded using a proprietary culture system to increase cell numbers while maintaining progenitor function. When infused alongside a standard cord blood unit, it accelerates neutrophil and platelet engraftment, reducing the time to hematopoietic recovery and associated complications in hematopoietic stem cell transplant recipients.","oneSentence":"Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:57.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematopoietic stem cell transplantation in patients with hematologic malignancies or severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT02730299","phase":"PHASE3","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","status":"COMPLETED","sponsor":"Gamida Cell ltd","startDate":"2016-12-16","conditions":"Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)","enrollment":125},{"nctId":"NCT02039557","phase":"","title":"Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients","status":"COMPLETED","sponsor":"Gamida Cell ltd","startDate":"2014-05-01","conditions":"Patients Transplanted With NiCord/CordIn (Omidubicel)","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NiCord® (omidubicel)","genericName":"NiCord® (omidubicel)","companyName":"Gamida Cell ltd","companyId":"gamida-cell-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation. Used for Hematopoietic stem cell transplantation in patients with hematologic malignancies or severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}